https://www.nasdaq.com/press-release/arbutus-to-participate-at-h.c.-wainwright-bioconnect-virtual-conference-2022-01-04
https://www.nasdaq.com/press-release/antios-therapeutics-and-arbutus-biopharma-announce-first-patient-dosed-in-phase-2a
https://www.nasdaq.com/press-release/arbutus-and-qilu-pharmaceutical-enter-into-an-exclusive-licensing-agreement-and
https://www.nasdaq.com/press-release/arbutus-biopharma-x-chem-and-proteros-biostructures-achieve-first-milestone-under
https://www.nasdaq.com/press-release/preliminary-data-shows-that-arbutus-capsid-inhibitor-ab-836-is-generally-safe-and
https://www.nasdaq.com/press-release/arbutus-biopharma-appoints-tram-tran-m.d.-to-its-board-of-directors-2021-11-11
https://www.nasdaq.com/press-release/arbutus-announces-new-data-on-ab-729-in-late-breaker-poster-presentation-at-aasld-the
https://www.nasdaq.com/press-release/arbutus-to-participate-at-jefferies-london-healthcare-conference-2021-11-10
https://www.nasdaq.com/press-release/arbutus-reports-third-quarter-2021-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/arbutus-announces-late-breaker-abstract-accepted-for-presentation-at-aasld-the-liver
https://www.nasdaq.com/press-release/arbutus-to-report-third-quarter-2021-financial-results-and-provide-corporate-update
https://www.nasdaq.com/press-release/arbutus-to-participate-in-october-investor-conferences-2021-09-28
https://www.nasdaq.com/press-release/arbutus-appoints-lisa-m.-caperelli-as-vice-president-investor-relations-2021-09-21
https://www.nasdaq.com/press-release/arbutus-to-participate-in-upcoming-investor-conferences-2021-09-07
https://www.nasdaq.com/press-release/arbutus-reports-second-quarter-2021-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/arbutus-to-present-at-wedbush-pacgrow-healthcare-virtual-conference-2021-08-03
https://www.nasdaq.com/press-release/arbutus-to-report-second-quarter-2021-financial-results-and-provide-corporate-update
https://www.nasdaq.com/press-release/arbutus-receives-authorization-to-proceed-with-an-investigational-new-drug
https://www.nasdaq.com/press-release/arbutus-biopharma-and-vaccitech-announce-clinical-trial-collaboration-agreement-to
https://www.nasdaq.com/press-release/arbutus-biopharma-and-antios-therapeutics-announce-clinical-collaboration-agreement
https://www.nasdaq.com/press-release/arbutus-announces-new-data-on-ab-729-and-ab-836-programs-with-presentation-of-five
https://www.nasdaq.com/press-release/arbutus-announces-multiple-abstracts-accepted-for-oral-and-poster-presentations-at
https://www.nasdaq.com/press-release/arbutus-to-participate-in-upcoming-investor-conferences-2021-05-26
https://www.nasdaq.com/press-release/arbutus-reports-first-quarter-2021-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/arbutus-to-report-first-quarter-2021-financial-results-and-provide-corporate-update
https://www.nasdaq.com/press-release/arbutus-biopharma-x-chem-and-proteros-biostructures-enter-into-a-pan-coronavirus
https://www.nasdaq.com/press-release/arbutus-receives-regulatory-approval-to-initiate-a-phase-1a-1b-clinical-trial-with-ab
https://www.nasdaq.com/press-release/arbutus-reports-fourth-quarter-and-year-end-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/arbutus-to-participate-at-h.c.-wainwright-global-life-sciences-conference-2021-03-02
https://www.nasdaq.com/press-release/assembly-biosciences-and-arbutus-biopharma-initiate-phase-2-clinical-trial-of-triple
https://www.nasdaq.com/press-release/arbutus-to-report-fourth-quarter-and-year-end-2020-financial-results-and-provide
https://www.nasdaq.com/press-release/arbutus-announces-2021-corporate-objectives-and-provides-financial-update-2021-01-25
https://www.nasdaq.com/press-release/arbutus-to-participate-in-virtual-fireside-chat-at-h.c.-wainwright-bioconnect-2021
https://www.nasdaq.com/press-release/arbutus-announces-robust-hbsag-decline-data-with-ab-729-dosed-at-60-mg-every-8-weeks
https://www.nasdaq.com/press-release/arbutus-announces-additional-robust-hbsag-decline-data-with-ab-729-in-chronic
https://www.nasdaq.com/press-release/arbutus-announces-presentation-of-phase-1a-1b-clinical-trial-results-for-ab-729-in
https://www.nasdaq.com/press-release/arbutus-to-present-at-jefferies-virtual-london-healthcare-conference-2020-11-10
https://www.nasdaq.com/press-release/arbutus-reports-third-quarter-2020-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/arbutus-to-report-third-quarter-2020-financial-results-and-provide-corporate-update
https://www.nasdaq.com/press-release/arbutus-to-participate-in-virtual-fireside-chat-at-h.c.-wainwright-hepatitis-b-virus
https://www.nasdaq.com/press-release/arbutus-to-participate-in-virtual-fireside-chat-at-chardans-4th-annual-genetic
https://www.nasdaq.com/press-release/arbutus-announces-ab-729-90-mg-single-dose-week-12-data-in-chronic-hepatitis-b
https://www.nasdaq.com/press-release/arbutus-to-participate-in-virtual-fireside-chat-at-h.c.-wainwright-22nd-annual-global
https://www.nasdaq.com/press-release/assembly-biosciences-and-arbutus-biopharma-announce-clinical-collaboration-agreement
https://www.nasdaq.com/press-release/arbutus-reports-second-quarter-2020-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/arbutus-to-present-at-wedbush-pacgrow-healthcare-virtual-conference-2020-08-05
https://www.nasdaq.com/press-release/arbutus-to-report-second-quarter-2020-financial-results-2020-07-29
https://www.nasdaq.com/press-release/arbutus-to-present-at-jefferies-virtual-healthcare-conference-2020-05-27
https://www.nasdaq.com/press-release/arbutus-announces-single-dose-week-12-data-in-chronic-hepatitis-b-subjects-with-60-mg
https://www.nasdaq.com/press-release/arbutus-to-present-at-ubs-virtual-global-healthcare-conference-2020-05-12
https://www.nasdaq.com/press-release/arbutus-reports-first-quarter-2020-financial-results-provides-pipeline-update-and
https://www.nasdaq.com/press-release/arbutus-to-report-first-quarter-2020-financial-results-2020-05-04
https://www.nasdaq.com/press-release/arbutus-announces-positive-preliminary-phase-1a-1b-clinical-trial-results-for-ab-729
https://www.nasdaq.com/press-release/arbutus-reports-fourth-quarter-and-year-end-2019-financial-results-confirms-2020
https://www.nasdaq.com/press-release/arbutus-to-report-fourth-quarter-and-year-end-2019-financial-results-2020-02-27
https://www.nasdaq.com/press-release/arbutus-announces-decision-to-discontinue-ab-452-and-to-pursue-development-of-a-next
https://www.nasdaq.com/press-release/arbutus-reports-third-quarter-2019-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/arbutus-to-report-third-quarter-2019-financial-results-2019-10-30
https://www.nasdaq.com/press-release/arbutus-announces-decision-to-discontinue-development-of-ab-506-an-oral-capsid
https://www.nasdaq.com/press-release/arbutus-to-participate-in-upcoming-investor-conferences-2019-09-26
